Table of Contents

company-logo

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Dividend Announcement

• Structure Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Structure Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Structure Therapeutics Dividend History

Structure Therapeutics Dividend Yield

Structure Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Structure Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Structure Therapeutics Financial Ratios

P/E ratio-15.50
PEG ratio0.14
P/B ratio1.91
ROE-16.40%
Payout ratio0.00%
Current ratio27.63
Quick ratio27.63
Cash Ratio5.15

Structure Therapeutics Dividend FAQ

Does Structure Therapeutics stock pay dividends?
Structure Therapeutics does not currently pay dividends to its shareholders.
Has Structure Therapeutics ever paid a dividend?
No, Structure Therapeutics has no a history of paying dividends to its shareholders. Structure Therapeutics is not known for its dividend payments.
Why doesn't Structure Therapeutics pay dividends?
There are several potential reasons why Structure Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Structure Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Structure Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Structure Therapeutics a dividend aristocrat?
Structure Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Structure Therapeutics a dividend king?
Structure Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Structure Therapeutics a dividend stock?
No, Structure Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Structure Therapeutics stocks?
To buy Structure Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Structure Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.